Alliance researcher Frank Sinicrope, MD Mayo Clinic will present results from Alliance for Clinical Trials in Oncology A021502/ATOMIC - a trial for patients with stage Ill deficient DNA mismatch repair colon cancer - at the #ASCO25 plenary session. Read more about Alliance at ASCO: bit.ly/AllianceAtASCO #NCI

A successful investigator initiated randomized clinical trial is not as easy as it sounds. Many years of work, many barriers to overcome. Time: Idea to Approval: 1-2 years Approval to Opening: 1 year Opening to Accrual: 3-5 years Accrual to Result: 2-5 years Result to

2 slides to summarize CtDNA role in early CRC . Excellent 👍. Nice discussion. ASCO Nicholas Hornstein Udhayvir Grewal Dr. Nina Niu Sanford OncoAlert Oncology Brothers #ASCO25

Dr Amol Akhade ASCO Nicholas Hornstein Udhayvir Grewal Dr. Nina Niu Sanford OncoAlert Oncology Brothers Concise and excellent summary of what we “know” and what we don’t “know” absent the hype. Completely agree.

Honored to get the 2025 OncoDaily mentorship Yvonne Award from the one and only Petros Grivas. And in the presence of the crew that matters the most who came and supported! Amin Nassar, MD Sagal Pannu Ayesha Aijaz Biagio Ricciuti, MD PhD Hassan Abushukair Alessio Cortellini Faisal, Salman M

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

🔥Plenary Discussion of LBA1🔥 #ASCO2025 👏Excellent disucssion by Myriam Chalabi 👉May neoadjuvant be more effective? 👉Do we need chemotherapy? ESMO - Eur. Oncology

So many practice changing GI studies #ASCO25. If you have some time listen to Dr. Malla discuss “Molecular Profiling/Liquid Biopsy Practices Guide First-Line CRC Therapy Decisions: W/Chandler Park and ⁦Midhun Malla⁩ ⁦𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏⁩ ⁦OncLive.com⁩ onclive.com/view/evolving-…

Midhun Malla Stacie Lindsey Melinda Bachini Thank YOU, Dr. Malla. We’re honored to be part of this shared commitment to advocacy and patient-centered progress. 💚

🔬 Colorectal Cancer (CRC) Screening: Evolving Landscape 🧻🩸🧪 📊 CRC = 2nd leading cause of cancer death, 3rd most common globally 👁️‍🗨️ Begins as adenomatous/serrated polyps → Advanced precursor lesions (APLs) → invasive cancer 🎯 Goal of screening: Detect early-stage CRC &

CLDN18 Expression and Isoform Distribution mainly in GI cancers. Trend of reduced overall CLDN18 expression after chemo with decrease CLDN18.2/18.1 proportion. Need similar analysis of isoform switch after chemo+Zolbe OncoAlert onlinelibrary.wiley.com/doi/10.1111/ca…

Zanidatamab plus chemotherapy as first-line treatment for HER2-positive GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎single-arm, phs 2 👉ORR 76·2% 👉mPFS 12·5 mo 👉mOS 36·5 mo 🧐Looks promising, now combo w/ ICI, phs-3 awaited ESMO - Eur. Oncology

In this episode of MedNewsWeek 🎙️, 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 of Norton Healthcare IT and Midhun Malla of UAB O'Neal Comprehensive Cancer Center, discuss treatment personalization in mCRC, with a focus on BRAF V600E–mutant tumors and HER2-altered disease. Listen here🎧: onclive.com/view/braf-muta…

🚨 GI Cancer Mortality to Double by 2050📊 ESMO GI 2025 shows sharp rise in deaths due to: 🔹 Colorectal: +103% 🔹 Pancreatic: +100% 🔹 Esophageal: +86% 🔹 Liver: +81% 🌍 Biggest increases in Asia & Africa 💡 Call to action: Early detection, access, equity. Time for GI oncologist

Great start to #ESMOGI2025 with pancreatic session co-led by Eileen M O’Reilly with talks covering full breadth of pancreatic cancer management- ranging from surgical approaches, radiation in PDAC by Karyn Goodman, MD, MS oligometastatic and metastatic disease management.

Invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, in anti-PD(L)1-resistant, antigen-rich GI cancers 🔎Phase I/II 👉60% MSI CRC 👉ORR: TMB-H GI 23%, TMB-H CRC: 25% 🧐 Interesting activity as monotherapy in subgroup of pretreated pts #ESMOAmbassadors

Safety results for durvalumab and tremelimumab as 1L treatment for HCC with poor prognosis 🔎 SIERRA phase IIIb 👉short exposure in CB 7/8 👉 higher PRAE in CP A, VP4 🧐 no new safety signals, but more efficacy data are needed #ESMOAmbassadors #ESMOGI25 ESMO - Eur. Oncology

Tumor microenvironment of patients with CLDN18.2 H in GEJ/gastric cancers. Real world data Caris Life Sciences Aakash Desai, MD, MPH, FASCO Bassel El-Rayes, MD UAB O'Neal Comprehensive Cancer Center Thanks to #ESMOGI25 for extending a merit award to present our work.

Many congratulations to our UAB O'Neal Comprehensive Cancer Center super ⭐️ Midhun Malla on his work on #TME for patients with CLN18.2 GEJ/gastric cancers, an exciting area for drug development and understanding TME is of paramount importance for this population! ESMO - Eur. Oncology #ESMOGI2025

Day 3 ESMO - Eur. Oncology but need to acknowledge my fantastic colleagues at Bristol Myers Squibb Tanios Bekaii-Saab, MD Dr. Shubham Pant Midhun Malla Patrick Boland ✅ One mission ⬆️ treatment advances for G.I. #cancer patients #ESMOGI25 #ESMOAmbassadors